Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566033 | 1.00 | MAPT (0.55) | MAPTKDM4EALDH1A1MAPK1STAT3 | |
| SCHEMBL22225992 | 0.90 | MAPT (0.56) | MAPTKDM4EALDH1A1MAPK1STAT3 | |
| SCHEMBL22227204 | 0.90 | MAPT (0.56) | MAPTKDM4EALDH1A1MAPK1STAT3 | |
| SCHEMBL20580612 | 0.87 | MAPT (0.56) | MAPTKDM4EALDH1A1MAPK1STAT3 | |
| Hydrochloric Acid SCHEMBL34474909 | 0.85 | MAPT (0.54) | MAPTKDM4EALDH1A1MAPK1STAT3 | |
| SCHEMBL29753822 | 0.85 | TSHR (0.60) | MAPTKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL27351890 | 0.85 | PRMT5 (0.43) | MAPTKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL9995863 | 0.85 | TSHR (0.60) | MAPTKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL16560478 | 0.83 | MAPT (0.44) | MAPTKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL3732847 | 0.83 | ALDH1A1 (0.53) | MAPTKDM4EALDH1A1MAPK1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | MYOFORTE THERAPEUTICS, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. | 2022-09-20 | — | — | US | disclosed |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11390618-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | US | disclosed |
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | disclosed |
| EP-1682129-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-07-26 | — | — | EP | disclosed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2005039572-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | MAPT 1300/4885KDM4E 3697/4885ALDH1A1 624/4885 |
| US-11358958-B2 | — | CDK2, CDK1, CDK6 | MAPT 1274/4885KDM4E 1178/4885ALDH1A1 3425/4885 |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | MAPT 4693/4885KDM4E 3758/4885ALDH1A1 145/4885 |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA3, ADORA1 | MAPT 1300/4885KDM4E 3697/4885ALDH1A1 624/4885 |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | MAPT 4693/4885KDM4E 3758/4885ALDH1A1 145/4885 |
| US-11447493-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | MAPT 2163/4885KDM4E 1278/4885ALDH1A1 3722/4885 |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | MAPT 4762/4885KDM4E 3885/4885ALDH1A1 183/4885 |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | PPARG, CDK5, CDK5R1 | MAPT 1059/4885KDM4E 3079/4885ALDH1A1 2975/4885 |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | HPGD, HPGDS, GCDH | MAPT 4312/4885KDM4E 2652/4885ALDH1A1 37/4885 |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | MAPT 4693/4885KDM4E 3758/4885ALDH1A1 145/4885 |
| US-11390618-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | MAPT 2163/4885KDM4E 1278/4885ALDH1A1 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.